Preliminary studies have shown that umifenovir has activity against Coxsackie B viruses. Umifenovir was found to have antiviral activity against Coxsackie virus B5 (CVB5) in vitro and in vivo, having both a cytopathic effect as well as directly reducing intracellular RNA. Orally administered umifenovir reduced virus in the lungs and heart, as well as mortality in an animal model of acute infection. A separate study found antiviral activity against Coxsackie B3, and a third study found umifenovir inhibited Coxsackie B4 in part by reducing the expression of IL-10 (by preventing p38-MK2 complex from exiting the nucleus).
See also[edit | edit source]
Learn more[edit | edit source]
References[edit | edit source]
- Zhong, Qiong (April 2009). "Antiviral activity of Arbidol against Coxsackie virus B5 in vitro and in vivo". Archives of Virology. 154.
- Shi, L (2007). "Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo". Archives of Virology. 152: 1447–55.
- Zhang, S (May 2017). "Umifenovir effectively inhibits IL-10 dependent persistent Coxsackie B4 virus infection". Antiviral Research. 141: 165–173.